AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making
Idag, 14:09
08:09 AM EDT, 05/13/2026 (MT Newswires) -- Owkin signed a deal with AstraZeneca (AZN.L, AZN.ST) to build AI biopharma agents, under a three-year licensing deal for K Pro, its AI scientist, for drug discovery and development decision-making.
The artificial intelligence and biotech company said Wednesday it will build and deploy AI agents under the deal using its K Pro platform within AstraZeneca's IT infrastructure and decision workflows.
The new agents will help AstraZeneca's decision-making teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis.
Ämnen i artikeln
AstraZeneca, Owkin to Develop AI Agents for Drug Discovery Decision-making
Idag, 14:09
08:09 AM EDT, 05/13/2026 (MT Newswires) -- Owkin signed a deal with AstraZeneca (AZN.L, AZN.ST) to build AI biopharma agents, under a three-year licensing deal for K Pro, its AI scientist, for drug discovery and development decision-making.
The artificial intelligence and biotech company said Wednesday it will build and deploy AI agents under the deal using its K Pro platform within AstraZeneca's IT infrastructure and decision workflows.
The new agents will help AstraZeneca's decision-making teams access timely, data-rich insights for complex competitive intelligence questions, reducing reliance on manual analysis.
Ämnen i artikeln
Analys
Regeringens krispaket
Analys
Regeringens krispaket
Marknadsöversikt
1 DAG %
Senast
1 mån
